GERN · Insider Trading
Geron Corp
Every open-market purchase and sale reported by GERN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-01 | Robert J. Spiegel | Director | A | +6,351 | +$7.81K |
| 2026-07-01 | Robert J. Spiegel | Director | A | +6,103 | +$7.81K |
| 2026-05-26 | Robert J. Spiegel | Director | A | +220,000 deriv. | — |
| 2026-05-26 | Susan Molineaux | Director | A | +220,000 deriv. | — |
| 2026-05-26 | Elizabeth G. O'Farrell | Director | A | +220,000 deriv. | — |
| 2026-05-26 | John F McDonald | Director | A | +220,000 deriv. | — |
| 2026-05-26 | Dawn Carter Bir | Director | A | +220,000 deriv. | — |
| 2026-04-14 | Timothy Williams | EVP and Chief Legal Officer | A | +2,500,000 deriv. | — |
| 2026-04-01 | Robert J. Spiegel | Director | A | +5,243 | +$7.81K |
| 2026-03-26 | Patricia S Andrews | Director | A | +270,000 deriv. | — |
| 2026-03-26 | Constantine Chinoporos | Director | A | +270,000 deriv. | — |
| 2026-02-19 | Joseph Eid | EVP, R&D; Chief Medical Office | A | +2,220,000 deriv. | — |
| 2026-02-19 | Michelle Robertson | EVP, CHIEF FINANCIAL OFFICER | MIXED | +17,645 | −$19.12K |
| 2026-01-05 | Robert J. Spiegel | Director | A | +5,918 | +$7.81K |
| 2025-10-20 | Ahmed ElNawawi | EVP, Chief Commercial Officer | A | +3,000,000 deriv. | — |
| 2025-10-01 | Robert J. Spiegel | Director | A | +5,702 | +$7.81K |
| 2025-08-08 | Harout Semerjian | President and CEO | A | +11,000,000 deriv. | — |
| 2025-07-01 | Robert J. Spiegel | Director | A | +5,540 | +$7.81K |
| 2025-05-22 | Gaurav Aggarwal | Director | A | +180,000 deriv. | — |
| 2025-05-22 | Susan Molineaux | Director | A | +180,000 deriv. | — |
| 2025-05-22 | V Bryan Lawlis | Director | A | +180,000 deriv. | — |
| 2025-05-22 | John F McDonald | Director | A | +180,000 deriv. | — |
| 2025-05-22 | Dawn Carter Bir | Interim President and CEO | A | +180,000 deriv. | — |
| 2025-05-22 | Elizabeth G. O'Farrell | Director | A | +180,000 deriv. | — |
| 2025-05-22 | Robert J. Spiegel | Director | A | +180,000 deriv. | — |
| 2025-05-13 | V Bryan Lawlis | Director | Buy | +13,300 | +$15.67K |
| 2025-04-02 | Robert J. Spiegel | Director | A | +4,913 | +$7.81K |
| 2025-04-02 | Robert J. Spiegel | Director | A | +1,767 | +$8.02K |
| 2025-04-02 | Robert J. Spiegel | Director | A | +4,378 | +$16.25K |
| 2025-04-02 | Robert J. Spiegel | Director | A | +2,206 | +$7.81K |
| 2025-03-03 | Scott Alan Samuels | EVP, Chief Legal Officer | Buy | +15,000 | +$24.15K |
| 2025-03-03 | John A Scarlett | Chairman, President and CEO | Buy | +12,500 | +$22.06K |
| 2025-03-03 | James Ziegler | EVP, Chief Commercial Officer | Buy | +100,000 | +$160.00K |
| 2025-02-20 | Andrew J Grethlein | EVP, Chief Operating Officer | A | +979,000 deriv. | — |
| 2025-02-20 | John A Scarlett | Chairman, President and CEO | A | +2,867,000 deriv. | — |
| 2025-02-20 | Scott Alan Samuels | EVP, Chief Legal Officer | A | +725,000 deriv. | — |
| 2025-02-20 | James Ziegler | EVP, Chief Commercial Officer | A | +618,000 deriv. | — |
| 2025-02-20 | Michelle Robertson | EVP, Chief Financial Officer | A | +766,000 deriv. | — |
| 2025-01-02 | Robert J. Spiegel | Director | A | −2,206 | — |
| 2024-11-12 | Joseph Eid | EVP, Research and Development | A | −2,500,000 deriv. | — |
| 2024-10-01 | Robert J. Spiegel | Director | A | −1,767 | — |
| 2024-09-09 | James Ziegler | EVP, Chief Commercial Officer | A | −1,600,000 deriv. | — |
| 2024-07-10 | Andrew J Grethlein | EVP, Chief Operating Officer | MIXED | — | −$1.91M |
| 2024-06-28 | Robert J. Spiegel | Director | A | −4,378 | — |
| 2024-06-12 | Anil Kapur | EVP, Corp Strategy & CCO | MIXED | — | −$1.51M |
| 2024-06-12 | Faye Feller | EVP, Chief Medical Officer | MIXED | — | −$992.44K |
| 2024-06-07 | Andrew J Grethlein | EVP, Chief Operating Officer | A | +452,804 deriv. | — |
| 2024-06-07 | Anil Kapur | EVP, Corp Strategy & CCO | A | +250,000 deriv. | — |
| 2024-06-07 | Faye Feller | EVP, Chief Medical Officer | A | +250,000 deriv. | — |
| 2024-06-07 | Michelle Robertson | EVP, Chief Financial Officer | A | +250,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Robert J. Spiegel | Director | 212,161 | $239.74K |
| John A Scarlett | Chairman, President and CEO | 137,500 | $155.37K |
| Susan Molineaux | Director | 130,527 | $147.50K |
| James Ziegler | EVP, Chief Commercial Officer | 100,000 | $113.00K |
| Elizabeth G. O'Farrell | Director | 33,627 | $38.00K |
| Scott Alan Samuels | EVP, Chief Legal Officer | 26,682 | $30.15K |
| Michelle Robertson | EVP, CHIEF FINANCIAL OFFICER | 17,645 | $19.94K |
| V Bryan Lawlis | Director | 13,300 | $15.03K |
| Andrew J Grethlein | EVP, Chief Operating Officer | 2,267 | $2.56K |
| Gaurav Aggarwal | Director | 1,970 | $2.23K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the GERN quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.